 |
Endacea, Inc. - MORE About
Us
In addition to sepsis, asthma, and renal impairment, Endacea believes that other indications for
Endacea's proprietary A1 AR antagonists include allergic rhinitis and
chronic obstructive pulmonary disease.
In April 2006, Endacea licensed several patents relating to the use of P2X purinoceptor antagonists and A1 adenosine receptor antagonists to treat ischemia reperfusion injury to Medicure International, Inc., a wholly owned subsidiary of Medicure, Inc. As a result of this license, Endacea received a $500,000 license fee and acquired a royalty interest in Medicure's lead compound, MC-1. Because MC-1 did not meet its principal end point in a pivotal Phase III clinical trial, Endacea does not expect to receive additional revenues from this license agreement. |
 |
